Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRXNASDAQ:HOWLNASDAQ:PRLDNASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsHOWLWerewolf Therapeutics$1.24+2.5%$1.05$0.60▼$4.18$54.30M0.66442,814 shs249,646 shsPRLDPrelude Therapeutics$0.86-7.2%$0.89$0.61▼$6.80$52.37M1.25281,883 shs170,107 shsTELOTelomir Pharmaceuticals$1.76-5.4%$2.35$1.71▼$8.40$55.36M-0.38153,749 shs187,458 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HOWLWerewolf Therapeutics+2.48%+0.81%+10.71%+13.76%-57.09%PRLDPrelude Therapeutics-7.16%-21.36%-6.78%+16.92%-77.75%TELOTelomir Pharmaceuticals-5.38%-10.66%-30.71%-56.86%-68.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHOWLWerewolf Therapeutics3.2632 of 5 stars3.53.00.00.01.15.00.6PRLDPrelude Therapeutics2.9789 of 5 stars3.22.00.00.00.05.00.6TELOTelomir Pharmaceuticals1.9368 of 5 stars3.80.00.00.02.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/AHOWLWerewolf Therapeutics 3.00Buy$8.33572.04% UpsidePRLDPrelude Therapeutics 2.33Hold$4.00364.52% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00752.27% UpsideCurrent Analyst Ratings BreakdownLatest ACRX, HOWL, TELO, and PRLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.005/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00HOWLWerewolf Therapeutics$1.88M29.60N/AN/A$1.65 per share0.75PRLDPrelude Therapeutics$7M6.95N/AN/A$2.39 per share0.36TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/AHOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)PRLDPrelude Therapeutics-$127.17M-$1.69N/AN/AN/AN/A-89.18%-69.26%8/11/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-2,009.40%-1,009.72%8/12/2025 (Estimated)Latest ACRX, HOWL, TELO, and PRLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04HOWLWerewolf Therapeutics0.468.098.09PRLDPrelude TherapeuticsN/A5.185.18TELOTelomir PharmaceuticalsN/A0.750.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%HOWLWerewolf Therapeutics64.84%PRLDPrelude Therapeutics79.72%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%HOWLWerewolf Therapeutics23.60%PRLDPrelude Therapeutics63.90%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionablePRLDPrelude Therapeutics12056.46 million20.38 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/AACRX, HOWL, TELO, and PRLD HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals Reports Positive Preclinical DataJune 18 at 10:17 AM | tipranks.comTelomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid AgingJune 18 at 9:15 AM | accessnewswire.comTelomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s diseaseJune 14, 2025 | pharmabiz.comTELO Rises on Promising Telomir-1 Preclinical ResultsJune 13, 2025 | insidermonkey.comTELO Rises on Promising Telomir-1 Preclinical ResultsJune 13, 2025 | msn.comTELO Continues Trend of Significant Trial AnnouncementsJune 11, 2025 | msn.comTelomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease ModelJune 11, 2025 | accessnewswire.comTelomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...June 7, 2025 | usatoday.comTELO Data Indicates Aging Reversal PotentialJune 6, 2025 | finance.yahoo.comTelomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner SyndromeJune 5, 2025 | accessnewswire.comTelomir announces positive preclinical data for its novel oral AMD therapeuticJune 3, 2025 | ophthalmologytimes.comTelomir Pharmaceuticals Joins BIO Convention for PartnershipsJune 2, 2025 | tipranks.comTelomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity PlatformJune 2, 2025 | accessnewswire.comTelomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...May 29, 2025 | finanznachrichten.deTELO Produces Results with Exciting AMD ImplicationsMay 29, 2025 | msn.comTelomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate EndpointsMay 29, 2025 | accessnewswire.comTelomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual SeparationMay 21, 2025 | marketwatch.comTelomir Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comTelomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease INDMay 21, 2025 | accessnewswire.comTelomir PharmaceuticalsMay 19, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRX, HOWL, TELO, and PRLD Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Werewolf Therapeutics NASDAQ:HOWL$1.24 +0.03 (+2.48%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.27 +0.03 (+2.74%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.Prelude Therapeutics NASDAQ:PRLD$0.86 -0.07 (-7.16%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.13%) As of 06/18/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Telomir Pharmaceuticals NASDAQ:TELO$1.76 -0.10 (-5.38%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.80 +0.04 (+2.56%) As of 06/18/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
